About Us
ACADIA Pharmaceuticals (Nasdaq: ACAD) is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. We are focused on developing a portfolio consisting of our most advanced product candidates including pimavanserin, which is in Phase III development for the treatment of Parkinson's disease psychosis in collaboration with Biovail. In addition, we have a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, and additional programs in IND-track development.
All of the product candidates in our pipeline emanate from discoveries made using our proprietary drug discovery platform. We have assembled a strong team of industry-experienced executives to lead the development and commercialization of our product candidates and we complement this team with a network of world-class scientific and clinical advisors.
back to top